

R E S U L T S

Table (1) :

Represent the possible source of infection : History of injections in the last 6 months reported in 48 % of patients. Surgical operations in (10 %), Contact with a case of jaundice (6 %). Blood transfusion in (4 %) and Unknown source was presented in (32 %).

Table (2) :

Represent the symptoms experienced by 48 patients with AVH. The sclera and dark urine (100 %) followed by anorexia and nausea (61 %), abdominal pain (52 %), dyspepsia (37.5 %), vomiting (31.5 %), Myalgia and arthralgia (8.5 %), constipation and diarrhoea (6.25 %), pruritus (6.25 %), pale stool (6.25 %), fat intolerance (6.25 %), fever (8.33 %) and signs of hepatic cell failure were not presented.

Table (3) :

Represent the abdominal examination for the different groups at the acute illness and after 3 and 6 months: Hepatic enlargement was presented in 100 %, 94 % and 87.5 % for the first (AvH and treated Bi), the 2nd (AvH and not treated Bi) and the 3rd. (AvH and -ve Bi) groups respectively at the acute stage and the spleen was palpable in 69 %; 56 % and 6% for the 1st.; 2nd. and 3rd. group respectively. After 3 months the liver was palpable in 75 %, 37.5 % and 12.5 % of

the 1st.; 2nd. and 3rd. groups respectively and the spleen. was palpable in 69 % and 50 % of the 1st.; 2nd. group resp. & not palpable in the 3rd. group. After 6 months the liver was palpable in 62.5 %; 50 % and 15 % of the 1st.; 2nd. and 3rd. group respectively and the spleen was palpable in 50 % and 25 % of the 1st. and 2nd. group respectively and was not palpable in the 3rd. group.

Table (4) :

Represent the investigations of Schistosomiasis. It was found that for the 1st. group urine analysis was +ve in 12.5 % of cases, stool analysis was +ve in 69 % of cases and the egg count was 20 - 220, and the rectal snip was +ve in 81 % of cases. After 3 months the urine and stool analysis was -ve and the rectal snip was +ve in 31 % of cases. After 6 months the rectal snip was +ve only in 7 % of cases. For the 2nd. group the urine was +ve in 12.5 % and the stool was +ve in 25 %; the egg count was 20 - 460. The rectal snip was +ve in 94 %. These investigations were in the acute stage. For the 3rd. group, the investigations of Schistosomiasis were -ve.

Table (5) :

Represent the symptoms and signs after praziquantel therapy for the 1st group patients : Gastro intestinal

manifestations (75 %) in the form of severe abdominal pain (44 %), vomiting (19 %), diarrhoea (6 %) and nausea (6 %), drowsiness and dizziness in (56 %), headache (37.5 %), allergic manifestations in the form of scattered maculopapular rashes (12.5 %) and fever which is high fever in (6 %).

Table (6) :

It represents the liver function tests of the first group (Acute viral hepatitis and treated Schistosomiasis) at the acute onset and after 3 & 6 months. The levels of SgoT were ranged between 21-40 u/L, 7-118 u/L and 4-77 u/L at the acute onset and after 3 & 6 months respectively and the mean of values of SgoT at the acute onset and after 3 & 6 months were found to be 56.1 ± 33 ; 26.7 ± 27.5 and 16.8 ± 20 respectively. The differences between the mean of values at the acute onset and after 3 months were statistically more significant where $P < 0.01$ and the differences between the mean of values after 6 months were highly significant where $P < 0.001$. The levels of SgpT were ranged between 12-100 u/L; 5 - 72 u/L and 4 - 57 u/L at the acute onset and after 3 & 6 months respectively and the mean of values of SgpT at the acute onset and after 3 & 6 months were found to be 33.9 ± 22.3 ; 19.1 ± 16.3 and 11.6 ± 14 respectively. The differences between the mean of values at the acute onset and after 3 months were statistically significant where $P < 0.05$

and the differences between the mean of values after 6 months were more significant where $P < 0.01$. The levels of the total bilirubin were ranged between 0.23 - 7.8 mg/dL; 0.5 - 3 mg/dL and 0.3 - 0.9 mg/dL at the acute onset and after 3 & 6 months respectively and the mean of values of the total bilirubin at the acute onset and after 3 & 6 months were found to be 2.43 ± 2.18 ; 1.07 ± 0.57 and 0.69 ± 0.2 respectively. The differences between the mean of values at the acute onset and after 3 months were statistically significant where $P < .05$ and the difference after 6 months were more significant where $P < 0.01$.

Table (7) :

It represent the liver function tests of the second group (Acute viral hepatitis and not treated Schistosomiasis) at acute onset and after 3 & 6 months : The levels of SgoT were ranged between 8 - 200 u/L; 2 - 86 & 7 - 26 at the acute onset and after 3 & 6 months respectively and the mean of values of SgoT at the acute onset and after 3 & 6 months were 72.2 ± 54.3 ; 17.4 ± 21 and 13.4 ± 5 respectively.

The differences between the mean of values of SgoT at the acute onset and after 3 months were statistically more significant where $P < 0.01$ and the differences between the acute onset and after 6 months were highly significant where $P < 0.001$. The levels of SgPT were ranged between 7-182 u/L;

2 - 69 u/L and 2 - 28 u/L at the acute onset and after 3 & 6 months respectively and the mean of values of SgPT at the acute onset and after 3 & 6 months were 73.6 ± 53.4 ; 18 ± 17 and 14 ± 5.6 respectively. The differences between the mean of values at the acute onset and after 3 months were statistically more significant where $P < 0.01$ and the differences after 6 months were statistically highly significant where $P < 0.001$.

The levels of the total bilirubin were ranged between 0.65 - 27; 0.2 - 2.9 and 0.1 - 3.6 at the acute onset and after 3 & 6 months respectively and the mean of values at the acute onset and after 3 & 6 months were 7.22 ± 7.31 ; 0.646 ± 0.643 and 0.832 ± 0.969 respectively. The differences between the mean of values at the acute onset and after 3 months were statistically high significant where $P < 0.001$ and the differences after 6 months were statistically more significant where $P < 0.01$.

Table (8) :

It represent the liver function tests of the third group (Acute viral hepatitis and -ve Schistosomiasis) at acute onset and after 3 & 6 months. The levels of SgoT were ranged between 21 - 39& u/L; 3 - 34 u/L and 1 - 49 u/L at the acute onset and after 6 months respectively and the mean of values of SgoT at the acute onset and after 3 & 6 months were 10.4 ± 94.2 ; 18.4 ± 10.7 and 12.4 ± 12.14 respectively. The differences

between the mean of values at the acute onset and after 3 months were statistically more significant where $P < 0.01$ and the differences after 6 months were highly significant where $P < .001$. The levels of SgPT were ranged between 11 - 197 u/L; 2-32 u/L & 1 - 75 u/L at the acute onset and after 3 & 6 months respectively and the mean of values at the acute onset and after 3 & 6 months were 85.9 ± 52.13 ; 14.2 ± 8.4 and 16.15 ± 18.8 respectively. The differences between the mean of values at the acute onset and after 3 months were highly significant where $P < 0.001$ and the differences after 6 months were highly significant where $P < 0.001$. The levels of total bilirubin were ranged between 0.8 - 21.6 mg/dL, 0.1 - 1 mg/dL and 0.2-2.8 mg/dL at the acute onset and after 3 & 6 months respectively and the mean of values at the acute onset and after 3 & 6 months were 9.12 ± 7.08 ; 0.475 ± 0.26 and 0.783 ± 0.69 respectively. The differences between the mean of values at the acute onset and after 3 months were highly significant where $P < 0.001$ and the differences after 6 months were more significant where $P < 0.01$.

Table (9) :

It illustrate the liver function tests for the different studied groups at the acute illness and after 3 & 6 months. At the acute illness the differences between the mean values of SgoT for the different studied groups, i.e., the first group (AVH and treated Schistosomiasis, the second group (AVH

and not treated Schistosomiasis) and the third group (AVH and -ve Schistosomiasis) were statistically significant where $P < 0.05$. The differences between the mean values of SgPT for the different studied groups were statistically significant where $P < 0.05$ and the differences between the mean values of SgPT for the different studied groups were statistically significant where $P < 0.05$ and the differences between the mean values of the total bilirubin were statistically insignificant where $P > 0.05$. After 3 months and after 6 months the differences for the different studied groups as regard the liver function tests were statistically insignificant $P > 0.05$.

Table (10) :

Illustrate the frequency of +ve cases of HBsAg, anti HBs and HBeAB in the diff. examined groups at the acute stage. i.e., (AVH and treated Bi); (AVH and not treated Bi) and (AVH and -ve Bi).

The frequency of +ve cases of HBsAg were 6 out of 16 (37.5%); 8 out of 16 (50 %) and 13 out of 16 (81 %) for the first , 2nd., 3rd. group respectively and the diff. was of statistical importance.

The frequency of +ve cases of anti HBs were 6 out of 16 (37.5 %); 10 out of 16 (62.5 %) and 5 out of 16 (31 %) for the 1st.; 2nd. and 3rd. group respectively and the diff. was (in-

sign). The frequency of HBcAB were 13 out of 16 (81 %); 13 out of 16 (81 %) and 16 out of 16 (100 %) for the first; second and third group respectively and the diff. was of no statistical importance.

Table (11) :

Illustrate the frequency of +ve cases of HBsAg, anti HBs and HBcAB in the diff. examined groups after 3 months. The frequency of +ve cases of HBsAg were 6 out of 16 (37.5 %) ; 7 out of 16 (44 %) and 9 out of 16 (56 %) for the first; second and third group respectively and the diff. was (insign).

The frequency of +ve cases of anti HBs were 4 out of 16 (29 %); 10 out of 16 (62.5 %) and 9 out of 16 (56 %) for the 1st.; 2nd. and 3rd. group respectively and the diff. was (insign). The frequency of HBcAB were 11 out of 16 (79 %); 13 of 16 (81 %); 16 out of 16 (100 %) for the 1st.; 2nd., and 3rd group respectively and the diff. was (insign).

Table (12) :

It illustrate the frequency of +ve cases of HBsAg, anti HBs and HBcAB in the different examined groups after 6 months from the acute illness : The frequency of +ve cases of HBsAg were 4 out of 14 (29 %); 6 out of 16 (37.5 %) and 6 out of 13 (46 %) for the first, second and third group respectively and the diff. was (insign).

The frequency of +ve cases of anti HBs were 7 out of 14 (50 %); 11 out of 16 (69 %) and 4 out of 13 (31 %) for the 1st; second and third group respectively and the diff. was (insign). The frequency of +ve cases of HBcAB were 9 out of 14 (64 %) ; 14 out of 16 (87.5 %) and 12 out of 13 (92 %) for the 1st. ; 2nd. and 3rd. group respectively and the diff. was insign. where $P > 0.05$.

Table (13) :

Illustrate the frequency of +ve cases of HBsAg, anti HBs and HBc AB in the 1st. group at the acute stage and after 3 & 6 months. The frequency of +ve cases of HBsAg were 6 out of 16 (37.5); 6 out of 16 (37.5) and 4 out of 14 (29 %) at the acute stage and after 3 and 6 months respectively and the % of reduction was 0 after 3 months and 33 % after 6 months and the diff. was (insign). The frequency of +ve cases of anti HBsAB were 6 out of 16 (37.5 %); 4 out of 16 (25 %) and 7 out of 14 (50 %) at the acute stage and after 3 and 6 months respectively and the diff. was (insign) where $P > 0.05$. The frequency of +ve cases of HBcAB were 13 out of 16 (81 %); 11 out of 16 (79 %) and 9 out of 14 (64 %) at the acute stage and after 3 and 6 months and the % of reduction was 15 % and 18 % after 3 & 6 months and the diff. was (insign) where $P > 0.05$.

Table (14) :

Illustrate the frequency of +ve cases of HBsAg; anti HBs and HBcAB in the 2nd group (AVH and Schisto. and not treated) at the acute stage and after 3 and 6 months. The frequency of HBsAg for the +ve cases were 8 out of 16 (50%) and 7 out of 16 (44 %) and 6 out of 16 (37.5 %) at the acute stage and after 3 and 6 months and the % of reduction was 12.5 % and 14 % after 3 and 6 months respectively and the diff. was (insign). The frequency of +ve cases of HBsAB were 10 out of 16 (62.5 %); 10 out of 16 (62.5 %) and 11 out of 16 (69 %) at the acute stage and after 3 and 6 months and the diff. was (insign), where $P > 0.05$.

The frequency of HBcAB were 13 out of 16 (81 %); 13 out of 16 (81 %) and 14 out of 16 (87.5 %) at the acute stage and after 3 and 6 months and the diff. was (insign) where $P > 0.05$.

Table (15) :

Illustrate the frequency of +ve cases of HBsAG, anti HBs& HBcAB in the 3rd. group (AvH and -ve Schisto.) at the acute stage and after 3 & 6 months. The frequency of +ve cases of HBs Ag were 13 out of 16 (81 %), 9 out of 16 (56 %) and 6 out of 13 (46 %) and the diff. was (insign) where $P > 0.05$.

The frequency of +ve cases of HBs AB were 5 out of 16 (31 %); 9 out of 16 (56 %) and 4 out of 13 (31 %) at the acute stage and after 3 & 6 months and the diff. were statistically insignificant where $P > 0.05$.

The frequency of +ve cases of HBc AB were 16 out of 16 (100 %); 16 out of 16 (100 %) and 12 out of 13 (92 %) at the acute stage and after 3 & 6 months and the differences were statistically insignificant where $P > 0.05$.

DIAGRAM 1 :

Show level of SgoT at the acute stage and after 3 and 6 months for the different studied groups. There was a drop in SgoT after 3 and 6 months :

- * For the 1st group (AvH + treated Schisto.), the % of reduction was 52 % and 70 % after the 3rd and 6 months respectively.
- * For the 2nd group (AvH + not treated Schisto.) the % of reduction was 76 % and 81 % after 3rd and 6 months respectively.
- * For the 3rd group (AvH and -ve Schisto.), the % of reduction was 82 % and 88 % after 3 and 6 months respectively.

DIAGRAM 2 :

Show the level of SgpI for the different studied groups at the acute illness and after 3 and 6 months :

- * For the 1st. group the % of reduction was 43.6 % and 65.8 % after 3 and 6 months respectively.
- * For the 2nd. group the % of reduction was 75.5 % and 81% after 3 and 6 months respectively.
- * For the 3rd. group the % of reduction was 83.5 % and 81.& % after 3 and 6 months respectively.

DIAGRAM 3 :

Show the level of total bilirubin for the different studied groups at the acute illness and after 3 and 6

months :

- * For the 1st. group, the % of reduction was 56 % and 71.6 % after 3 and 6 months respectively.
- * For the 2nd. group the % of reduction was 91 % and 88.5 % after 3 and 6 months respectively.
- * For the 3rd. group the % of reduction was 94.8 % and 91.4% after the 3 and 6 months respectively.

DIAGRAM 4 :

Show +ve cases of HBs Ag for the different studied groups at the acute illness and after 3 & 6 months :

- * For the 1st. group : No drop after 3 months and there was a drop after 6 months with a (%) of reduction (33 %).
- * For the 2nd. group : There was a drop and the (%) of reduction was 12.5 % and 25 % after 3 and 6 months respectively.
- * For the 3rd. group, there was a drop in HBs Ag and the % of reduction was 31 % and 53.8 % after 3 and 6 months respectively.

DIAGRAM 5 :

Show +ve cases of anti HBs for different examined groups at the acute illness and after 3 and 6 months :

- * For the 1st group, there was a drop after 3 months with % of reduction of 33 % and after 6 months there was an increase in the level with % of 16 %.
- * For the 2nd group, no drop of anti HBs after 3 months and there was an increase of 10 % after 6 months.

- * For the 3rd group, there was an increase of anti HBs (80%) after 3 months and there was a drop of (20 %) after 6 months from the acute illness.

DIAGRAM 6 :

Show the +ve cases of HBc AB for the different examined groups at the acute stage and after 3 and 6 months :

- * For the 1st group, there was a drop of HBc AB with a % of reduction 15 % and 30 % after 3 and 6 months respectively.
- * For the 2nd group, there was no drop after 3 months and there was an increase of (7.6 %) after 6 months.
- * For the 3rd group no drop in HBc AB was found after 3 months and there was a drop after 6 months with a % of reduction (25 %).

Table (1) :

Possible source of infection among patients with acute viral hepatitis for all the studied groups :

Possible Source of Infection	No. of Patients	%
. History of injection in last 6 months	23	48 %
. Surgical operations	5	10 %
. Contact with a case of Jaundice	3	6 %
. Blood transfusion	2	4 %
. Drug abuse	0	0
. Tatting	0	0
. Unknown	15	32 %
T O T A L	48	100 %

Table (2) :

Symptoms experienced by 48 patients with acute viral hepatitis :

Symptoms	No. of Patients	%
1. Jaundice (degree)	48	100 %
2. Dark urine	48	100 %
3. Anorexia	29	61 %
4. Nausea	29	61 %
5. Abdominal Pain	25	52 %
6. Dyspepsia	18	37.5 %
7. Vomitting	15	31.5 %
8. Myalgia	4	8.5 %
9. Arthralgia	4	8.5 %
10. Constipation	3	6.25%
11. Diarrhae	3	6.25%
12. Pruritus	3	6.25%
13. Pale stool	3	6.25%
14. Fat Intolersnce	3	6.25%
15. Fever	4	8.33%
16. Signs of hepatic failure .	0	0
17. Melena	0	0

Table (3) :

Hepatomegally, Splenomegally for the different examined groups at the acute illness and after 3 and 6 months :

	Hepatomigally		Splenomegally		Not felt		TOTAL
	No.	%	No.	%	No.	%	
THE FIRST GROUP :							
(AvH + treated Bi)							
• At the acute onset	16	100 %	11	69 %	0	0 %	16
• After 3 months	12	75 %	11	69 %	4	25 %	16
• After 6 months	10	62.5%	7	50 %	4	28.6%	14
THE SECOND GROUP :							
(AvH & not treated Bi)							
• At the acute onset	15	94 %	9	56 %	1	6.2%	16
• After 3 months	6	37.5%	8	50 %	2	12.5%	16
• After 6 months	8	50 %	4	25 %	4	25 %	16
THE THIRD GROUP :							
(AvH & -ve Bi)							
• At the acute onset	14	87.5%	1	6 %	1	6 %	16
• After 3 months	2	12.5%	0	0 %	14	87.5%	16
• After 6 months	2	15 %	0	0 %	11	82.5%	13

Table (4) :

Investigation of Schistosomiasis by urine and stool analysis and by rectal snip for the different studied groups at the acute onset and after 3 & 6 months for the 1st group only.

THE GROUP	Urine Analysis	Stool Analysis	Egg count	Rectal Snip	TOTAL
<u>THE FIRST GROUP :</u> <u>(AvH + treated Bi)</u> . At the acute onset After 3 months After 6 months	No	No		No	
	%	%		%	
	2 12.5 %	11 69 %	20 - 220 0	13 81 % 5 31 %	16 16
	-ve -ve	-ve -ve	0	1 7 %	14
<u>THE SECOND GROUP :</u> <u>(AvH + not treated Bi)</u> . At the acute onset ...	&	5	20 - 460	15	16
	12.5 %	25 %		94 %	
<u>THE THIRD GROUP :</u> <u>(AvH and -ve Bi)</u> . At the acute onset ...	-ve	-ve		-ve	16

Table (5) :

Symptoms experienced by 16 patients with AvH and +ve
Schistosomiasis after praziquantel therapy :

Symptoms	No. of Patients	%
* Gastro intestinal manifestation :	<u>12</u>	<u>75 %</u>
. Severe abdominal pain	7	44 %
. Vomitting	3	19 %
. Diarrhoea	1	6 %
. Nausea	1	6 %
* Drowsiness & dizziness ..	9	56 %
* Headache	6	37.5 %
* Allergic reaction	2	12.5 %
* Fever	1	6 %

Table (6) : Liver function tests of the first group (Acute viral hepatitis and treated Schistosomiasis) at the acute stage and after 3 & 6 months.

	Sgot u/l *			Sgpt i/l **			Total Bilirubin mg/dl ***		
	At acute onset	At 3 months	At 6 months	At acute onset	At 3 months	At 6 months	At acute onset	At 3 months	At 6 months
Range	21-40	7-118	4-77	12-100	5-72	4-57	0.23-7.8	0.5-3	0.3-0.9
Mean	56.1	26.7	16.8	33.9	19.1	11.6	2.43	1.07	0.69
S.D.	33.0	27.5	20.0	22.3	16.3	14.0	2.18	0.57	0.57
P	< 0.01 More sign			< 0.001 Highly sign			< 0.05 Sign		

* Normal Sgot up to 12 u/L
 ** Normal Sgpt up to 12 u/L
 *** Normal total bili ubin level up to 1 mg/dL

Table 6-a : Liver function tests of the 1st. group (AvH and treated Schistosomiasis) after 3 and 6 months :

	SgOT		SgPT		Total Bili ubin	
	At 3 months	At 6 months	At 3 months	At 6 months	At 3 months	At 6 months
Mean	26.7	18.8	19.1	11.6	1.07	0.09
S.D.	27.5	20.0	16.3	14.0	0.51	0.20
P	> 0.05 (insign.)		> 0.05 (insign.)		> 0.05 (insign.)	

****** There was no statistical significances as regard SgOT and SgPT and there was a statistical significant for total billirubin.

Schistosomiasis) at the acute stage and after 3 & 6 months :

	Sgpt u/L			Sgpt u/L			Total Bilirubin mg/dL		
	At acute onset	At 3 months	At 6 months	At acute onset	At 3 months	At 6 months	At acute onset	At 3 months	At 6 months
Range	8-200	2-86	7-26	7-182	2-69	2-28	0.65-27	0.2-2.9	0.1-3.6
Mean	72.2	17.4	13.4	73.6	18.0	14.0	7.22	0.646	0.832
S.D.	54.3	21.0	5.0	53.4	17.0	5.6	7.31	0.643	0.969
P	< 0.01 More sign	< 0.001 Highly sign	< 0.01 More sign	< 0.001 highly sign	< 0.001 Highly sign	< 0.01 More sign	< 0.001 Highly sign	< 0.01 More sign	< 0.01 More sign

Table 7-a : Liver function tests of the 2nd group (AvH and not treated Schistosomiasis) after 3 and 6 months :

	Sgot		Sgpt		Total bilirubin	
	At 3 months	At 6 months	At 3 months	At 6 months	At 3 months	At 6 months
Mean	17.4	13.4	18	14.0	0.646	0.832
S.D.	21.0	5.0	17	5.6	0.643	0.969
P	> 0.05 (insign.)		> 0.05 (insign.)		> 0.05 (insign.)	

**** No significant difference for all the liver function tests.**

Table 8-a : Liver function tests of the 3rd group (AvH and -ve Schistosomiasis) after 3 and 6 months :

	Sgot		Sgpt		Total bilirubin	
	At 3 months	At 6 months	At 3 months	At 6 months	At 3 months	At 6 months
Mean	18.4	12.4	14.2	16.15	0.475	0.783
S.D.	10.7	12.14	8.4	18.8	0.26	0.69
P	> 0.05 (insign.)		> 0.05 (insign.)		> 0.05 (insign.)	

**** No significant difference for the liver function tests.**

Table (9) : Liver function tests in the different studied groups at the acute onset and after 3 and 6 months :

The Group	No	\bar{X} at the acute illness			No	\bar{X} after 3 months			No	\bar{X} after 6 months		
		Sgot	Sgpt	'Bili-rubin		Sgot	Sgpt	'Bili-rubin		Sgot	Sgpt	'Bili-rubin
The First Group (AvH & treated Bi)	16	56.1	33.9	2.43	16	26.7	19.1	1.07	14	16.8	11.6	0.69
The Second Group (AvH & not treated Bi)	16	72.2	73.6	7.22	16	17.4	18.0	0.646	16	13.4	14.0	0.832
The Third Group (AvH & -ve Bi)	16	101.4	85.9	9.12	16	18.4	14.2	0.475	13	12.4	16.15	0.783
P		<0.05 <0.05 >0.05 Sign Sign insign				>0.05 >0.05 >0.05 insign insign insign				>0.05 >0.05 >0.05 insign insign insign		

\bar{X} = The mean

Table (10) : Frequency of +ve HBS Ag, Anti HBS -- HBC AB in the different examined groups with acute hepatitis :

Studied groups at acute onset	No	+ve HBS Ag		+ve anti HBS		+ve HBC AB	
		No	%	No	%	No	%
1 st . group (AvH + Schistosom. and took praziquantel).	16	6	37.5 %	6	37.5 %	13	81.0 %
2 nd . group (AvH + Schistosom. and not take praziquantel).	16	8	50.0 %	10	62.5 %	13	81.0 %
3 rd . group (AvH and -ve for Schistosom.).	16	13	81.0 %	5	31 %	16	16 %
T O T A L	48	27	56.0 %	21	44.0 %	42	87.5 %
P		< 0.05 (Sign.)		> 0.05 (insign.)		> 0.05 (insign.)	

Table (11) : Frequence of +ve cases of HBS Ag, Anti HBS and HBC Ab in the different examined groups after 3 months from the acute illness :

Studied groups after 3 months	No	HBS Ag		Anti HBS		HBC AB	
		No	%	No	%	No	%
<u>1st.</u> group (AvH + Schisto. and treated with praziquantel.	16	6	37.5 %	4	25.0 %	11	69 %
<u>2nd.</u> group (AvH + Schisto. and not treated with praziquantel).	16	7	44.0 %	10	62.5 %	13	81 %
<u>3rd.</u> group (AvH & -ve Schisto.).	16	9	56.0 %	9	56.0 %	16	100 %
T O T A L	48	22	46.0 %	23	48.0 %	40	83 %
P		> 0.05 (insign.)		> 0.05 (insign.)		> 0.05 (insign.)	

Table (12) : Frequency of +ve cases of HBs Ag, anti HBs and HBc AB in the different examined groups after 6 months from the acute illness :

Studied groups after 6 months	+ve HBs Ag		+ve Anti HBs		+ve HBc AB		
	No	%	No	%	No	%	
1st. group (AvH &nd Schisto.) treated with praziquantel.	14	4	29.0%	7	50.0%	9	64.0 %
2nd. group (AvH and Schisto.) and not treated with praziquantel	16	6	37.5%	11	69.0%	14	87.5 %
3rd. group (AvH and -ve Schisto.)	13	6	46.0%	4	31.0%	12	92.0 %
T O T A L	43	16	37.0%	22	51.0%	35	81.0 %
P	> 0.05 (insign.)		> 0.05 (insign)		> 0.05 (insign.)		

Table (13) : Frequency of +ve cases of HBs Ag anti HBs and HBc in the 3rd. group (acute viral hepatitis and treated Schistosomiasis) at the acute stage and after 3 & 6 months:

THE GROUP	No	+ve HBs Ag		+ve anti HBs		+ve HBc Ag	
		No	%	No	%	No	%
the 1st. group (AVH and treated Schistosomiasis).							
* At the acute stage	16	6	37.5 %	6	37.5 %	13	81 %
* After 3 months	16	6	37.5 %	4	25.0 %	11	79 %
* After 6 months	14	4	29.0 %	7	37.0 %	9	64 %
T O T A L	46	16	35.0 %	17	37.0 %	33	27 %
P		>0.05 (insign)		>0.05 (insign)		>0.05 (insign)	

Table (14) : Frequency of +ve cases of HBs Ag, anti HBs and HBc for the 2nd. group (acute viral hepatitis and not treated Schistosomiasis) at the acute stage and after 3 and 6 months :


THE GROUP	No	HBs Ag		Anti HBs		HBc AB	
		No	%	No	%	No	%
The 2 nd . group (AvH and not treated Schistosomiasis) :							
* At the acute stage	16	8	50.0 %	10	62.5 %	13	81 %
* After 3 months	16	7	44.0 %	10	62.5 %	13	81 %
* After 6 months	16	6	37.5 %	11	69.0 %	14	87 %
T O T A L	48	21	44.0 %	31	65.0 %	40	83 %
P		> 0.05 (insign.)		> 0.05 (insign.)		> 0.05 (insign.)	

Table (15) : Frequency of +ve cases of HBs Ag anti HBs and HBc in the 3rd. group (acute viral hepatitis and -ve Schistosomiasis) at the acute stage and after 3 and 6 months :

THE GROUP	No	+ve HBs Ag		+ve anti HBs		+ ve HBc AB	
		No	%	No	%	No	%
The <u>3rd.</u> group (AvH and -ve Schistosomiasis) :							
* At the acute stage	16	13	81 %	5	31 %	16	100 %
* After 3 months	16	9	56 %	9	56 %	16	100 %
* After 6 months	13	6	46 %	4	31 %	12	92 %
T O T A L	45	28	62 %	18	40 %	44	98 %
P		0.05 (insign.)		0.05 (insign.)		0.05 (insign.)	

DIAGRAM I

Level SgoT for the studied groups
at the acute stage and after 3 and 6
months.




\bar{x} = Mean



1st group (AvH + treated Bilh.)




2nd group (AvH and not treated Bilh.)





3rd group (AvH and -ve Bilh.).

Level of SgpT for the studied groups at the acute stage and after 3 and 6 months follow up and % of reduction from the acute stage to 3 and 6 months.

DIAGRAM 2




 1st group (AvH + treated Bi.)

 2nd group (AvH + not treated Bi.)


 3rd group (AvH -ve Bi)

DIAGRAM 3

Level of total Bilirubin for the studied groups at the acute stage and after 3 and 6 months follow-up and % of reduction from the acute to 3 and 6 months.



1st group (AvH + treated Bi.)




2nd group (AvH + not treated Bi.)




3rd group (AvH -ve Bi.)

DIAGRAM 4

+ve cases of HBs Ag for the diff. groups
at the acute stage and after 3 and 6 mon.
and % of reduction.



1st group (AvH + treated Bi.)




2nd group (AvH + not treated Bi.)



3rd group (AvH + not treated Bi.)

+ve cases of anti HBs for the diff.
examined groups at the acute stage
and 3 and 6 months.

DIAGRAM 5



1st group (AvH + treated Bi.)




2nd group (AvH + not treated Bi.)




3rd group (AvH -ve Bi.)

DIAGRAM 6


+ve cases of HBc AB for the diff.
examined groups at the acute stage
and after 3 and 6 months.



1st group (AvH + treated Bi.)



2nd group (AvH + not treated Bi.)



3rd group (AvH -ve Bi.)